Lupin share price

• Company is virtually debt free. • The company has an efficient Cash Conversion Cycle of 52.2946140819502 days. • Company has a healthy liquidity position with current ratio of 2.38497304906004. • The company has a good cash flow management; CFO/PAT stands at 1.55113480995351. • The company has a strong degree of Operating leverage, Average Operating leverage stands at 62.8509738354494. • The company has shown a poor profit growth of -149.68139157391% for the Past 3 years. • The company has shown a poor revenue growth of 1.20457662428617% for the Past 3 years. • Company has a poor ROE of 3.42873690286624% over the past 3 years. • Company has contingent liabilities of 3595.95 Cr. • Tax rate is low at -16.8204048783508. • The company is trading at a high EV/EBITDA of 32.9866. Quarterly Result (All Figures in Cr.) PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Net Sales 2855.39 2732.49 2828.96 2861.11 2836.27 Total Expenditure 2354.39 2522.62 2515.3 2645.98 2574.09 Operating Profit 501 209.87 313.66 215.13 262.18 Other Income 16.15 85.31 15.37 17.1 55.3 Interest 24.58 19.87 18.38 30.75 29.44 Depreciation 131.02 130.35 137.76 134.03 146.2 Exceptional Items 0 0 0 0 0 Profit Before Tax 361.55 144.96 172.89 67.45 141.84 Tax 397.44 27.78 24.27 27.05 22.83 Profit After Tax -35.89 117.18 148.62 40.4 119.01 Adjusted EPS (Rs) -0.79 2.58 3.27 0.89 2.62 Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.) PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Net Sales 10...

LUPIN LTD Key highlights: 💡⚡ ✅On 1 Hour Time Frame Stock Showing Breakout of Bullish flag Pattern . ✅ Strong Bullish Candlestick Form on this timeframe. ✅It can give movement up to the Breakout target of 875+. ✅Can Go short in this stock by placing a stop loss below 765-. LUPIN LTD Key highlights: 💡⚡ ✅On 1 Hour Time Frame Stock Showing Breakout of Bullish flag Pattern . ✅ Strong Bullish Candlestick Form on this timeframe. ✅It can give movement up to the Breakout target of 875+. ✅Can Go short in this stock by placing a stop loss below 765-. Hello mates, As I know that this is month starting and this is not a appropriate time to analyze a chart on monthly time frame but I want to go some in deep to find out a pattern or kind of a reversal signs from strong support zones in it in Lupin so I may be find out some useful things could help s Hello mates, As I know that this is month starting and this is not a appropriate time to analyze a chart on monthly time frame but I want to go some in deep to find out a pattern or kind of a reversal signs from strong support zones in it in Lupin so I may be find out some useful things could help s Prices have formed a ‘Flag’ Formation. Volumes on the rally since 628 have been high on bullish days. Prices have also cleared its previous peak of 788 decisively. The upside momentum is expected to continue till 875 initially. Optimistically, price could also test 940. Bullish outlook remai Prices have formed a ‘Flag’ Formation. Volumes on the ra...

Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. It offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India. Breakout from a weekly resistence with good volume, also making a "W", buy now or after a retest depending on your risk apetite, seeing an upside till 900. This is for Idea purpose only, I am not a SEBI Reg. analyst. Do your own research before investing. Comment if you have any questions regarding Breakout from a weekly resistence with good volume, also making a "W", buy now or after a retest depending on your risk apetite, seeing an upside till 900. This is for Idea purpose only, I am not a SEBI Reg. analyst. Do your own research before investing. Comment if you have any questions regarding Looks like worst is over for lupin. Results are improving along with technicals. I bought this few weeks ago and will be increasing my positions if price falls. Potential to make good money in next 12-15 months. Looks like worst is over for lup...

Si haces clic en « Aceptar todo», nosotros y • mostrar anuncios y contenido personalizados basados en perfiles de interés; • medir la efectividad de los anuncios y el contenido personalizados, y • desarrollar y mejorar nuestros productos y servicios. Si no quieres que nosotros ni nuestros socios utilicemos cookies y datos personales para estos propósitos adicionales, haz clic en « Rechazar todo». Si quieres personalizar tus opciones, haz clic en « Gestionar configuración de privacidad». Puedes cambiar tus opciones en cualquier momento haciendo clic en el enlace «Configuración de privacidad y cookies» o «Panel de control de privacidad» de nuestros sitios y aplicaciones. Para obtener más información sobre cómo utilizamos tus datos personales, consulta nuestra

The stock's beta value, which measures volatility in relation to the broader market, stood at 0.75. Promotor/FII Holding Promoters held 46.8 per cent in Lupin Ltd. as of 31-Mar-2023 while foreign and domestic institutional investors owned 13.32 per cent and 16.96 per cent, respectively. Moving averages The 200-DMA of the stock stood at 712.64 on June 09, while the 50-DMA was at 734.24. If a stock trades below 50-DMA and 200-DMA, it usually means the immediate trend is upward. On the other hand, if the stock trades below 50-DMA and 200-DMA, it is considered as bearish trend and if trades between 50-DMA and 200-DMA, then it suggests the stock can go either way. Don’t miss out on ET Prime stories! Get your daily dose of business updates on WhatsApp.

The Institutional Brokers' Estimate System (I/B/E/S) is a database of estimates made by stock analysts regarding the future earnings of publicly traded companies. It provides analyst forecasts on company performance expressed via various consensus measures, including earnings per share, sales, and net income. These estimates are aggregated by Refinitiv using it’s Institutional Brokers' Estimate System and displayed by us on “AS IS” basis. The estimates that are displayed should not be construed to be investment recommendation/advice or an offer or solicitation of an offer to buy/sell any securities by Nextbillion Technology Pvt Ltd (Groww). Investors should not solely rely on the information displayed herein and must make investment decisions based on their own investment objectives, judgment, risk profile, and financial position. Past performance should not be taken as an indication or guarantee of future performance. Kindly note that investment in securities markets is subject to market risks, read all the related documents carefully before investing. Lupin Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therap...

• Home • Budget 2022 • Market • CaFE Invest • Commodities • IPO NEWS • IPOs • Economy • Tech • Auto • SME • Mobility • Industry • Banking & Finance • Technology • SME/Start-ups • Audio • Jobs • Education • Mutual Funds • Sports • Money • Insurance • Income Tax • Infrastructure • Railways • Aviation • Roadways • India • Lifestyle • Travel & Tourism • Health • Science • From The Print • International • Edits & Columns • Opinion • FE 360 • Politics • Economy • Personal Finance Print • Front Page • FE Insight • Fe@Campus • Brand Wagon • Todays Paper • ePaper • Photos • Videos • Infographics • Horoscope • archive • Digital Currency Lupin Ltd. is a Public Limited Listed company incorporated on 01/03/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC029442 and registration number is 029442. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11771.67 Cr. and Equity Capital is Rs. 90.90 Cr. for the Year ended 31/03/2022.

Sector Healthcare Compare with Sector peers Industry Pharmaceuticals & Drugs Compare with Industry peers Website http://www.lupin.com Market Cap 37,977.25 Cr. Enterprise Value(EV) 40,928.17 Cr. 2023-03 Financial Indicators • Consolidated • Standalone Earnings per share (EPS) 9.45 Trailing Twelve Months Ending 2023-03 Price-Earning Ratio (PE) 88.35 Trailing Twelve Months Ending 2023-03 Industry PE 34.47 Trailing Twelve Months Ending 2023-03 Book Value / Share 273.91 Trailing Twelve Months Ending 2023-03 Price to Book Value 3.05 Calculated using Price: 835.00 Dividend Yield 0.48 Period Ending 2022-03 No. of Shares Subscribed 45.51 Cr. 455,062,552 Shares FaceValue 2 About Lupin Ltd. Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. Lupin is recognised as one of the world's largest manufacturers of Tuberculosis drugs. The company have significant market share across multiple therapy areas such as Cardiovascular (prils and statins), Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). To add to this, the company has proud to maintain over the years its global leadership positions in other therapy areas such as Anti-TB and Cephalosporin. 9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 Return on Equity (%) 30.89 31.09 22.85 21.05 1.91 3.88 -3.09 9.47 -11.79 Return on Capital Employed (%) 40.97 40.30...